




已阅读5页,还剩13页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
PharmaceuticalDevelopmentwithFocusonPaediatricformulations,WHO/FIPTrainingWorkshopHyattRegencyHotelSaharAirportRoadAndheriEast,Mumbai,India28April20082May2008,BiopharmaceuticalClassificationSystem(BCS),Presentedby:LembitRgoMD,PhDContactdetails:DrLembitRgoCoordinator,QualityAssuranceandSafety:MedicinesMedicinesPolicyandStandardsWorldHealthOrganizationGenevaSwitzerlandE-Mail:,BiopharmaceuticalClassificationSystem(BCS),BackgroundWhatisaproblem?WhatisWHOdoingandplanningtodo?Whatresourcesareavailable?Conclusions,Whatisthekeyformultisource(generic)pharmaceuticalproducts?,Newmedicinesapplicanthastoprovequality,safetyandefficacyMultisource(generic)pharmaceuticalproductsapplicanthastoprovequality,incaseofsafetyandefficacyitreferstotheoriginatorproductThekeyisTHERAPEUTICINTERCHANGEABILITYItisassumedthatiftheconcentrationpatterninthebloodisessentiallythesamethenthesafetyandefficacyprofilemustbeessentiallythesame,Therapeuticinterchangeability:prerequisites,ConstantandreproduciblequalityofMPPsManufacturedunderGMPCompliancewithallqualityspecificationsVariationscontrolNoconstantandreproduciblequality,noneedforprovinginterchangeabilityasitismeaningless(allbatchesdifferentanyhow),Optionstoshowtherapeuticinterchangeabilityofmultisourcepharmaceuticalproducts(MPP),TheinvitroapproachreferstotheBiopharmaceuticsClassificationSystem(BCS),DrugsubstanceclassificationaccordingtotheBCS.Activepharmaceuticalingredients(APIs)areclassifiedintoclassesbasedontheiraqueoussolubilityandpermeabilitycharacteristics,InVitroApproaches/Biowaiveroptions,ThepossibilityofinvitrodocumentationofbioequivalenceforcertainmedicinesanddosageformsisspecifiedinSection9oftheWHOguidancedocument1.Ifthedrugsubstanceinquestionishighlysolubleandhighlypermeable(BCSclassI)andismanufacturedasanimmediatereleasedosageform,exemptionfromaninvivopharmacokineticbioequivalencestudymaybeconsideredprovidedthatrelevantdissolutionrequirementsarefulfilled.,Principles,Thesolubilityisnotmeanttobetheabsolutesolubilityhere.Incontrasthighsolubilityreferstothehighestsingleunitdosetobecompletelysolublein250mlaqueousbuffermediumwithinthepHrangeof1.2to6.8withoutanystabilityproblems.AsanotherrelatedphysicochemicalcharacteristichighpermeabilityshouldbedemonstratedfortheparticularAPIdemonstratingthatthefractiondoseabsorbedamountstoatleast85%.Accordingly,highpermeabilitywouldstandforalmostcompleteabsorptionofthecompoundinhumans.PhysicochemicalmeasuresneededforBCSclassificationpurposesmaybetakenfromsoundliterature.TheWHOModelListofEssentialMedicineshasbeenreviewedbasedontheBCSconceptandactivecompoundsareclassifiedaccordinglyintheappendixofrespectiveWHOdocument1.,Atheoreticalriskassessmentismandatorytominimizeriskforfalselywaivinganecessaryinvivostudy,SituationswhereBCS-basedbiowaiversarenotapplicable,Assessmentofriskspracticalpoints,Inpracticesomeofthecriterialistedinthetableforriskassessmentaredifficulttoassesse.g.,themeaningofcriticaluseorbioavailabilityproblems,andareprobablynoteasytobedefined.However,publishedliteratureprovidesvaluableexamplesofhowtoevaluatetheapplicabilityoftheBCSbasedbiowaiverapproach(seebiowaivermonographsonthefollowingslide).,Availableresources:BiowaiverMonographs,BiowaivermonographsareworkedoutbygroupofwellestablishedscientistslinkedtoFIPandpublishedinJournalofPharmaceuticalSciencesThesecanbeusefulscientificmaterialformanufacturerswhenconsideringapplicationsforbiowaiverbasedonBCSThemonographsassuchhavenoregulatoryauthoritydecisionswillbemadebyregulatorswhomayormaynotacceptbiowaiverdependingontheirnationallegislationandrequirements,Biowaivermonographspublished,StosikA.G.,JungingerH.E.,KoppS.,MidhaK.K.,ShahV.P.,StavchanskyS.,DressmanJ.B.,BarendsD.M.:Biowaivermonographsforimmediatereleasesolidoraldosageforms:metoclopramidehydrochloride.JPharmSciFeb12(2008)BeckerC.,DressmanJ.B.,AmidonG.L,JungingerH.E.,KoppS.,MidhaK.K.,ShahV.P.,StavchanskyS.,BarendsD.M.:Biowaivermonographsforimmediatereleasesolidoraldosageforms:Pyrazinamide.JPharmSciFeb12(2008)BeckerC.,DressmanJ.B.,AmidonG.L,JungingerH.E.,KoppS.,MidhaK.K.,ShahV.P.,StavchanskyS.,BarendsD.M.:Biowaivermonographsforimmediatereleasesolidoraldosageforms:ethambutoldihydrochloride.JPharmSciAug21(2007)BeckerC.,DressmanJ.B.,AmidonG.L,JungingerH.E.,KoppS.,MidhaK.K.,ShahV.P.,StavchanskyS.,BarendsD.M.:Biowaivermonographsforimmediatereleasesolidoraldosageforms:isoniazid.JPharmSci96(2007)522-31,WHOGuidance(1),TheinvitrodissolutioninvestigationsincludingexperimentalconditionsandcharacteristicsareoutlinedinSection9oftheWHOguideline1.Itisofutmostimportancetonotethatitisnotsufficienttodemonstratetheinvitrodissolutioncharacteristicsfortheparticularmultisourceproduct,buttoensurethesimilarityofdissolutionprofilesbetweenthetestandcomparatorproducts1.,WHOguidance(2),TheWHOguidanceinbasicaspectsissimilartotheUSFDAguidanceonthebiowaiverapproach(August2000)Inaddition,thecurrentscientificdiscussionsintermsofsocalledbiowaiverextensionsarealsoconsidered.Accordingly,BCSbasedbiowaiversmaybeacceptablefordrugscontainingBCSclass2and3drugsubstancesmanufacturedasimmediatereleasedosageforms.Asanexample,abiowaivermaybepossibleforBCSclass3drugproductsthatareveryrapidly(i.e.atleast85%dissolutionwithin15mininallrequiredmedia)dissolving.Therelevantdissolutioncriteriaareoutlinedinsection9.2.1oftheWHOguideline1.,Regulatorsguidanceforindustry,USFDArelevanttobiowaiverguidelines:/cder/Guidance/3618fnl.pdf,Conclusions,BiowaiverconceptisadevelopingconceptandnewguidancedocumentsandscientificdataareappearingPropercomparatorproductsarealsocrucialforbiowaiverRegulatoryacceptanceandpracticeofbiowaiversneedstocatchuptheconceptdevelopmentWHOwillsoonissuemorepracticalimplementationguidelinesforPQprogrammeWHOPQprogrammestartsacceptingbiowaivers,asappropriate,Someusefulreferences,(1)Multisource(generic)pharmaceuticalproducts:Guidelinesonregistrationrequirementstoestablishinterchangeability.In:WHOExpertCommitteeonSpecificationsforPharmaceuticalPreparations,FortiethReport.Geneva,WorldHealthOrganization,2006,WHOTechnicalReportSeries,No.937,Annex7:347-390.(2)vanFaassenF.,VromansH.etal.Biowaiversfororalimmediate-releaseproducts:implicationsoflinearpharmacokinetics.ClinPharmacokinet43(2004)1117.(3)NotetoApplicantsontheChoiceofComparatorProductsforthePrequalificationProject.LocatedontheWorldHealthOrganization(WHO)PrequalificationofMedicineswebsite,Guidanceonselectionofcomparatorproduct.Webpage:/pq/(4)Shah,V.P.et
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 小学生作文质量诊断报告
- 高层建筑施工安全技术措施
- 劳务外包与派遣合同管理指南
- 人力资源管理制度修订方案与实施效果
- 牛津译林版英语单元测试题库
- 小学语文三年级单元知识复习提纲
- 小升初科学学习计划制定指南
- 餐饮管理 SOP标准操作流程
- 高压电力线路施工组织设计完整方案
- 企业收购项目可行性研究报告模板
- 学校运营分析报告范文
- 美术用品采购合同模板
- 2024~2025学年北师大版数学九年级上册 2.5一元二次方程的根与系数的关系 说课稿
- 2023年“达人英才计划”引才考试真题
- 蜗牛与黄鹂鸟(课件)人音版音乐二年级上册
- 铁路车辆电工(高级)职业技能鉴定考试题库(含答案)
- 七年级上册语文统编版 10 《往事依依》活动型公开课一等奖创新教学设计(表格式)
- 国有企业岗位劳动合同模板
- 人教版小学六年级上册数学期末测试卷及完整答案【名校卷】
- 护理查房制度及流程
- 心肺复苏 Cardiopulmonary Resuscitation演讲
评论
0/150
提交评论